Clinical Trial

French Hypertrophic Cardiomyopathy Observatory

Study acronym: REMY
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated September 21, 2022 (before its estimated December 2023 completion). Its status may not reflect the trial's current state.
Summary
Hypertrophic cardiomyopathy (Hypertrophic CardioMyopathy=HCM) remains a poorly understood disease with an assumption insufficiently codified. There is no data available in France on the profile of patients, diagnostic methods and assessment and therapeutic use. The purpose of this study is to establish a monitoring of patients with HCM (sarcomere of origin or not) in France (diagnosis, treatment)
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2010-03-23; most recent amendment 2022-09-20.
Trial Details
NCT Number NCT01091480
Lead Sponsor French Cardiology Society
Conditions Hypertrophic Cardiomyopathy
Enrollment 600 participants
Start Date 2010-01
Primary Completion 2023-12 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2022-09-21